Abstract
Cisplatin-based highly emetogenic chemotherapy (HEC) displays a biphasic pattern of emesis with both an early and delayed period. In contrast, moderately emetogenic chemotherapy (MEC) has a monophasic pattern. The objective of this analysis was to further investigate the impact of the NK1-receptor antagonist aprepitant on these patterns. Three phase III HEC (patients scheduled to receive cisplatin-based chemotherapy) and one phase III MEC (breast cancer patients scheduled to receive anthracycline plus cyclophosphamide (AC)) trials of aprepitant were included. In all studies, patients were randomized in a 1:1 ratio to an aprepitant regimen (aprepitant plus ondansetron plus dexamethasone) or the standard regimen (ondansetron plus dexamethasone). The exact dosing regimen for ondansetron and dexamethasone was different in each study. In a post hoc analysis, multivariate logistic regression models were used to assess the impact on first emesis at different time intervals after chemotherapy. One thousand five hundred twenty-seven patients and 856 patients were randomized and assessed for efficacy in the HEC and MEC trials, respectively. For HEC, aprepitant reduced the risk of first emesis by 38-77% vs. standard regimen, beginning 15-...Continue Reading
References
Aug 24, 1991·Lancet·D B SmithK D Bagshawe
Apr 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F RoilaD Donati
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethB Haley
Jun 1, 1996·Oncology·M Martin
Nov 1, 1996·Drugs·R Tavorath, P J Hesketh
Jun 17, 1999·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·H MatsumotoK Fujikawa
Mar 23, 2000·Neuropharmacology·F D TattersallR J Hargreaves
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CamposB J Gertz
Apr 21, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V CocquytB J Gertz
Feb 28, 2002·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fausto RoilaGuido Margutti
May 9, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P J HeskethK J Horgan
Jun 5, 2003·Cancer·Sergio Poli-BigelliUNKNOWN Aprepitant Protocol 054 Study Group
Oct 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J HeskethUNKNOWN Aprepitant Protocol 052 Study Group
Nov 13, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Charlotte C SunEdward B Rubenstein
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G WarrFranck Skobieranda
Aug 17, 2005·Cancer·Jørn HerrstedtUNKNOWN Aprepitant Moderately Emetogenic Chemotherapy Study Group
Mar 10, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollC Y Chan
Jun 6, 2008·The New England Journal of Medicine·Paul J Hesketh
Nov 28, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Steven M GrunbergMarisa Siebel
Citations
Oct 30, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lieven AnnemansHughes Malonne
Jan 10, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A D LealCharles L Loprinzi
Apr 6, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Felipe Melo CruzAuro del Giglio
Oct 16, 2012·Cancer Treatment Reviews·Matti S AaproR Timothy Webb
Dec 3, 2015·Postgraduate Medical Journal·Preet Mohinder SinghBasavana Goudra
May 4, 2017·Expert Opinion on Drug Safety·Bernardo Rapoport, Teresa Smit
Mar 14, 2020·Cancer Medicine·Koji MatsumotoToshiaki Saeki
Jul 12, 2017·The Journal of Obstetrics and Gynaecology Research·Masae IkedaMikio Mikami
Apr 14, 2016·Molecular and Clinical Oncology·Takashi TsudaNarikazu Boku
Mar 21, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·David Warr